Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors
Rhea-AI Summary
Fulcrum Therapeutics (NASDAQ: FULC) appointed Josh Lehrer, M.D., M.Phil., FACC to its Board of Directors as an independent director effective April 27, 2026. Dr. Lehrer is a physician-scientist and biotech executive with over two decades of clinical development experience.
He currently serves as CEO of Marea Therapeutics and previously was CEO of Graphite Bio (Apr 2020–Sep 2023) and CMO at Global Blood Therapeutics, where he oversaw development and approval of Oxbryta (voxelotor). Fulcrum said his experience will support advancement of pociredir and its benign hematology pipeline.
Positive
- Adds board expertise with >20 years of clinical development experience
- Direct leadership experience in rare disease drug development, including Oxbryta approval
- Serves concurrently as CEO of Marea Therapeutics, bringing active executive perspective
Negative
- None.
News Market Reaction – FULC
In the Apr 27 session, FULC declined 1.53%, reflecting a mild negative market reaction. Argus tracked a peak move of +15.3% during that session. Argus tracked a trough of -3.3% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules that improve the lives of patients with rare hematological disorders, today announced that Josh Lehrer, M.D., M.Phil., FACC, has been appointed to its Board of Directors as an independent director.
Dr. Lehrer is a physician-scientist and biotechnology executive with more than two decades of clinical development experience across all stages of drug development. He currently serves as Chief Executive Officer and a member of the board of directors of Marea Therapeutics, a clinical-stage biotechnology company. Previously, Dr. Lehrer served as President and Chief Executive Officer of Graphite Bio, Inc. from April 2020 until September 2023. Prior to that, he was the Chief Medical Officer at Global Blood Therapeutics where he oversaw the development and approval of Oxbryta® (voxelotor) for the treatment of sickle cell disease. Earlier in his career, Dr. Lehrer held clinical development and business development roles at Genentech.
“We are delighted to welcome Josh to Fulcrum’s Board of Directors,” said Alex C. Sapir, President and Chief Executive Officer of Fulcrum Therapeutics. “Josh brings deep expertise in rare disease drug development and a strong track record advancing transformative therapies, including his leadership in the development and approval of Oxbryta for patients with sickle cell disease. His experience will be invaluable as we continue advancing pociredir and our broader benign hematology pipeline.”
“I spent more than a decade working to develop new therapies for patients with sickle cell disease, and the need for effective, orally available treatments remains significant,” said Dr. Lehrer. “Fulcrum is advancing a promising approach with pociredir, supported by results from the PIONEER trial, and I look forward to working alongside the board and management team to help bring this therapy forward for patients.”
Dr. Lehrer received an A.B. in Biochemical Sciences from Harvard University and a Master of Philosophy in Biological Sciences from the University of Cambridge. He earned his Doctor of Medicine from the University of California, San Francisco and completed his residency in internal medicine at UCSF, followed by postdoctoral fellowship in cardiovascular medicine at Stanford University.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules that improve the lives of people with rare hematological disorders. The company’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of genetically defined diseases. For more information, visit www.fulcrumtx.com and follow us on X (@FulcrumTx) and LinkedIn.
Contact:
Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856
